Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humansInterventional

A Phase 0 Open Label Positron Emission Tomography Study to Assess the Biodistribution and Binding Characteristics of [11C]AZ14132516 Following Administration to Healthy Participants

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

AstraZeneca AB, AstraZeneca AB

Enrolment target

Start

03 Apr 2023

Crohn's disease

What is this study about?

Standard uptake value (SUV) in region of interest; Standard uptake value ratio (SUVR) in regions of interest (ie, total binding of [11C]AZ14132516 to CCR9)

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
Sweden

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.